CONTRACT's Questionnaire to Analyse and Improve Informed Consent in Clinical Trials

In the frame of the European Project CONTRACT, which aims at analysing, improving and harmonising "informed consent" across Europe a questionnaire has been set up which will analyse the current situation concerning the legal, ethical, technical and clinical handling of consent, mainly in European projects dealing with vulnerable patient groups. The purpose is to identify existing practices and problems encountered in translational research throughout Europe.

By participating in this survey you will help us to advise translational research projects in all issues of informed consent and to deliver concretepolicy recommendations as to how the European Union could jointly protect patient's rights and support translational research by a better structured approach towards consent issues. The survey is addressed to:

  • Clinicians/Care providers,
  • Chairpersons of research projects/trials,
  • Researchers/Molecular biologists,
  • Computer Scientists,
  • Legal Experts/Ethicists,
  • Data Manager/Statisticians,
  • European Policymakers.

In addition you will gain access to the advisory service via the helpdesk provided by CONTRACT, please visit www.contract-fp7.eu for further details.

CONTRACT's electronic survey is now accessible online under the following link::
https://contract.custodix.com/index.php?sid=67123&lang=en

About CONTRACT Project
The CONTRACT project is a two-year support action (2010-2012) funded under the Health theme of the EU's Framework Programme 7.

CONTRACT seeks to establish methods to understand the way the European Data Protection Directive and the Clinical Trials Directive have had and continue to have an impact on the success of translational research. The project will focus on informed consent as a fundamental precondition for the legal processing of personal data and for carrying out a legally admissible trial.

Most Popular Now

Aspirin green light for brain bleed stroke patient…

People who suffer a stroke caused by bleeding in the brain - known as brain haemorrhage - can take common medicines without raising their risk of another stroke, a major ...

Cancer cells are quick-change artists adapting to …

Until now, researchers have assumed that the growth of solid tumors originates from cancer stem cells characterized by specific surface markers, which develop in a fixed...

APRINOIA Therapeutics awarded grant from The Micha…

APRINOIA Therapeutics, a clinical-stage biotechnology company with a pipeline of therapeutics and imaging diagnostics for neurodegenerative diseases, announces today that...

Benralizumab not effective reducing exacerbations …

More than 15.3 million people in the U.S. suffer from chronic obstructive pulmonary disease (COPD), which is the third leading cause of death in this country, according t...

Pfizer announces top-line results from Phase 3 Tri…

Pfizer Inc. (NYSE: PFE) announced today that a Phase 3 study to assess the use of LYRICA® (pregabalin) as adjunctive therapy for epilepsy patients 5 to 65 years of age wi...

Novartis phase II data for new inhaled combination…

Novartis announced today that new phase II data for IND/GLY/MF (QVM149), an investigational, once-daily, fixed dose combination asthma treatment containing indacaterol ac...

Cannabis use among older adults rising rapidly

Cannabis use among older adults is growing faster than any other age group but many report barriers to getting medical marijuana, a lack of communication with their docto...

New data show Symbicort reduces attacks in mild as…

New data from Novel START, an open-label trial designed to reflect real-world practice, has demonstrated the effectiveness of Symbicort Turbuhaler (budesonide/formoterol)...

Merck pioneers new effort to see MS from the insid…

Merck, a leading science and technology company, joins the global multiple sclerosis (MS) community in recognition of World MS Day, an initiative created by the Multiple ...

Amgen joins with community oncology networks for n…

Amgen (NASDAQ: AMGN), along with leading community oncology networks, today announced the launch of Amgen Community Oncology Research Collaborators (ACORC), a new initiat...

Bayer receives U.S. FDA breakthrough therapy desig…

Bayer announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for copanlisib (Aliqopa™) for the treatment of adult patie...

Novartis Kisqali significantly extends life in wom…

Novartis announced statistically significant overall survival (OS) results for Kisqali in combination with endocrine therapy[1]. The Phase 3 MONALEESA-7 trial evaluated K...